Analytical Method Transfer: The Step Most Buyers Skip

A buyer qualifies a second source for ursodeoxycholic acid. The specification matches, the certificates for the trial batches look reasonable, and the first in-house retest comes back half a percent lower than the supplier's figure. Nobody is lying. The two laboratories are running what the documents call the same method, on equipment with different dwell volumes, against standards with different assigned purities, and the difference between them was never measured.

Method transfer is the step that measures it. It is also the step most often skipped, because it sits between two departments: the buyer's quality control group assumes the supplier's method is validated, and the supplier assumes a pharmacopoeial method needs no introduction.

What "the same method" actually means

For a pharmacopoeial substance, three different things can be called the same method. The monograph text, which specifies the principle, the reagents and often the column dimensions. The house method derived from it, which fills in the details the monograph leaves open. And the routine practice in a given laboratory, which includes the integration parameters, the equilibration time and the way the standard is prepared.

Two laboratories can agree on the first, differ on the second, and diverge materially on the third. The result is a comparison of two methods wearing one name.

Three routes, three evidence packs

The right route depends on what is being moved and how much is at stake.

Situation	Route	Evidence that closes it
Pharmacopoeial method, first use in your laboratory	Verification	System suitability met, one batch reproduced within a stated criterion
Established method moving to a second laboratory	Transfer	Side-by-side results on the same batches, pre-defined criterion
New or modified method, two laboratories involved from the start	Co-validation	Joint precision and accuracy data across both sites
Method unchanged, only the sample source changed	Partial verification	Matrix and impurity-profile comparison on the new material

The fourth row is the one buyers underuse. Changing the source of a material without changing the method still changes the matrix, because the impurity profile differs. A partial verification on the new material is cheap and catches most surprises.

Setting the criterion before the experiment

The single most common defect in a transfer is a criterion chosen after the results are known. It is also the easiest to avoid: write the acceptance criterion into the protocol, signed, before the first injection.

A defensible criterion sits between the method's repeatability and the specification width. If the method's relative standard deviation is 0.5 percent and the specification spans four percentage points, a difference criterion of one percentage point between laboratories is generous and still meaningful. A criterion of 0.1 percent would fail on statistics alone, and a criterion of three points would pass almost anything.

The system suitability trap

System suitability passing in both laboratories is necessary and often mistaken for sufficient. It shows that each system is performing to its own criteria. It does not show that the two systems produce comparable numbers on the same material, because the criteria are usually set per laboratory and rarely cross-referenced.

The comparison that matters is the result on a common sample. That requires the same material to be analysed in both places, which in turn requires a retained sample to be shipped under conditions that do not change it. A transfer protocol that omits the common sample is not a transfer.

What to write into the change control

When a source change is planned, four items belong in the change record: the method comparison protocol, the batches selected, the criterion, and the action to be taken if the criterion is missed. The last is the one that gets omitted and the one that matters most, because a failed comparison without a pre-agreed response tends to be resolved by re-running until it passes.

A pre-agreed response might be a joint investigation, a third laboratory, or acceptance of a documented offset in the specification for that source. Any of the three is defensible. None of them is defensible if it is invented after the fact.

Why this is a commercial issue, not only a technical one

A half-percent disagreement between two laboratories becomes a commercial problem when a batch is rejected at goods-in against a specification that the supplier's own method meets. The argument that follows is not about chemistry. It is about whose number is the reference, and that question is settled by whoever did the transfer work first.

Doing it at qualification costs a protocol, three batches and a fortnight. Doing it after a rejection costs a shipment, a relationship and, often, a concession on price to make the problem go away.

The quiet version of the same problem

Not every method gap produces a rejection. Some produce a persistent offset that everybody learns to live with: the supplier's assay reads 0.4 percent high, so the buyer mentally adjusts. That works until somebody new joins, reads the certificate literally, and rejects a batch that is entirely fine.

Documenting the offset at transfer is the cheap version of solving it. It converts a piece of institutional folklore into a written comparison, which is the only form that survives staff turnover.

How to run a transfer in two weeks

Ask the supplier for a retained sample from a released batch, with its certificate. Analyse it in your laboratory against your own method, in triplicate, and compare with the supplier's reported values. That is the minimum experiment, and it answers the only question that matters: will your number agree with theirs on material you both accept.

If the comparison passes, write the result into the qualification file and stop. If it fails, you have found the problem before the first commercial shipment, which is the cheapest possible moment.

Three articles here cover the surrounding ground. When a certificate omits the assay method explains why a comparison can be impossible without asking. Stability-indicating methods explains what a method has to be able to see before a comparison means anything. And using a contract laboratory covers the option when your own capacity is the constraint.

Where the method texts sit

Pharmacopoeial methods are published by the European Directorate for the Quality of Medicines for the European Pharmacopoeia and by the United States Pharmacopeia for the USP. The general chapters on validation and on analytical procedures, published by the International Council for Harmonisation, define what a validated method has demonstrated.

Between them they settle what "the same method" can legitimately mean. The monograph sets the principle, the general chapters set the performance expectations, and the transfer protocol supplies the comparison that neither of them provides.

What failure looks like, and what it costs

The common failure is not a gross disagreement. It is a systematic offset of a few tenths of a percent that nobody investigates, and which then causes a rejection when a batch lands near a specification boundary. The rejection looks like a quality event. It is an unclosed method question.

The second failure is the opposite: a comparison run without a pre-set criterion, which produces a result nobody can interpret and a decision made on impression. Both failures are avoidable with a one-page protocol, and both are expensive to unwind afterwards.

The trial that costs a week and saves a quarter

Take the retained sample from the supplier's released batch and run it on your own press, at your own settings, alongside a batch from your current source. Record the line speed, the compression force needed to reach the target hardness, the weight variability and the reject rate. That is one day of machine time and one week of planning.

The output is not a number, it is a comparison. If the second source needs twenty percent more force to reach the same hardness, that is a formulation question you can address before the first commercial batch. If it needs the same force and runs at the same speed, the source is likely interchangeable and the qualification can proceed on the analytical comparison alone.

Buyers skip this because the analytical comparison appears to answer the question. It answers a different one. Two materials can be chemically identical and behave differently under compression, because compaction depends on particle habit, surface disorder and the fines fraction as much as on identity.

What the failure costs when it is found late

Found after the first commercial delivery, the same finding costs a reformulation, a revalidation of the compression step, a period of dual sourcing while the new material is characterised, and possibly a batch that cannot be sold because the tablets do not meet the dissolution specification.

None of those costs appears in the purchase price comparison that selected the source. That is why the comparison is misleading: it prices the material and ignores the process change the material may require.

A week of trial work, scheduled before the order, is the cheapest insurance available in a source change. It is also the step most reliably omitted, because it belongs to nobody's department until it belongs to everybody's problem.

Frequently asked questions

Do I need a method transfer if the method is pharmacopoeial?

You need a transfer or a verification. A pharmacopoeial method is presumed suitable, but your laboratory still has to demonstrate that it can reproduce the result on your equipment with your analysts. That demonstration is the verification, and it is lighter than a full transfer but not optional.

What is the difference between transfer and co-validation?

A transfer moves a method from a sending laboratory to a receiving one, and the evidence is a comparison of results on the same material. Co-validation is a joint exercise in which both laboratories participate in establishing the method's performance. Co-validation is heavier and is used when the method is new rather than established.

How many samples and replicates are needed?

Common practice is three batches or three concentration levels, with replicates at each, analysed by both laboratories. The exact design follows the method's variability. What matters is that the comparison is pre-defined rather than assembled afterwards from whatever was available.

What acceptance criterion should we set?

One that reflects the method's repeatability rather than a round number. A criterion tighter than the method's own variability will fail for statistical reasons. A criterion looser than the specification is meaningless. Set it between the two, and write it down before the experiment.

Who pays for the transfer?

It depends on who benefits. A buyer qualifying a second source pays for its own laboratory's work. A supplier making a change that affects the method may reasonably be asked to support the comparison. The allocation should be settled before the work starts, not after a failure.

Can we accept the supplier's data instead of running our own?

You can accept it for release if your own method is not the release method. You cannot accept it as evidence that your laboratory will reproduce the number, because that is a statement about your laboratory. The two questions are different and only one of them can be answered by somebody else's data.